Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022

Rhea-AI Summary

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is set to report its 2022 second quarter financial results on August 3, 2022, after U.S. market close. A live audio webcast will occur at 4:30 p.m. ET for a financial update and discussion of results. Interested parties can register in advance through Jazz's website. Jazz Pharmaceuticals is committed to developing life-changing medicines in neuroscience and oncology, with a global presence and innovative therapies.

Positive

• Live webcast scheduled for financial results indicates transparency and investor engagement.
• The company maintains a diverse portfolio in neuroscience and oncology, potentially driving future growth.

Negative

• None.

DUBLIN, July 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 second quarter financial results on Wednesday, August 3, 2022, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss 2022 second quarter financial results and provide a business and financial update.  

Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the call to ensure adequate time for any software downloads that may be necessary.

A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. 

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.

Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media Contact:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2022-second-quarter-financial-results-on-august-3-2022-301590386.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When will Jazz Pharmaceuticals report its 2022 second quarter earnings?

Jazz Pharmaceuticals will report its 2022 second quarter earnings on August 3, 2022.

What time is the Jazz Pharmaceuticals webcast for the financial results?

The webcast for Jazz Pharmaceuticals' financial results is scheduled for 4:30 p.m. ET.

Where can I find the Jazz Pharmaceuticals 2022 second quarter earnings report?

The earnings report will be available on Jazz Pharmaceuticals' website after the announcement on August 3, 2022.

What is the focus of Jazz Pharmaceuticals' business?

Jazz Pharmaceuticals focuses on developing innovative medicines in the fields of neuroscience and oncology.